Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen, Luminex Extend and Expand License

NEW YORK, (GenomeWeb News) – Invitrogen and Luminex jointly announced today that they have extended and expanded a licensing agreement for Luminex’s multiplex technology and systems.
 
The new license extends the lifetime of the license and expands Invitrogen’s rights to include Luminex’s next-generation multiplex detection platforms. The firms did not disclose the length of or terms of the agreement.
 
Invitrogen currently offers more than 200 multiplex protein assays based on Luminex’s xMAP technology for cellular pathway and disease analysis.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.